Insmed (NASDAQ:INSM) PT Raised to $67.00

Insmed (NASDAQ:INSM – Free Report) had its price target boosted by TD Cowen from $45.00 to $67.00 in a report released on Wednesday, Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock. A number of other brokerages have also recently weighed in on INSM. Guggenheim raised their price objective on […]

Leave a Reply

Your email address will not be published.

Previous post Lucas: Trump needs Nikki Haley now more than ever
Next post Duckhorn Portfolio (NYSE:NAPA) Price Target Cut to $11.00